U.S. pharma huge copyright scrapped two experimental weight loss tablets final calendar year—a when-daily tablet, lotiglipron, on account of elevated liver enzymes and a 2 times-everyday pill, danuglipron, resulting from potent Unintended effects—but CEO Albert Bourla has said the company is decided to “play and earn” in the weight problems